• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,026.17
  • -0.85 %
  • -$326.17
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Aerovate Therapeutics, Inc. (AVTE) Stock Price, News & Analysis

Aerovate Therapeutics, Inc. (AVTE) Stock Price, News & Analysis

Currency in USD Disclaimer

$2.62

-$0.04

(-1.5%)

Day's range
$2.57
Day's range
$2.68
50-day range
$1.84
Day's range
$3
  • Country: US
  • ISIN: US0080641071
52 wk range
$1.25
Day's range
$32.42
  • CEO: Mr. Timothy P. Noyes M.B.A.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -1.31
  • Piotroski Score 2.00
  • Grade Equal-Weight
  • Symbol (AVTE)
  • Company Aerovate Therapeutics, Inc.
  • Price $2.62
  • Changes Percentage (-1.5%)
  • Change -$0.04
  • Day Low $2.57
  • Day High $2.68
  • Year High $32.42

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/26/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $2.00
  • High Stock Price Target $35.00
  • Low Stock Price Target $2.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$3.03
  • Trailing P/E Ratio -6.84
  • Forward P/E Ratio -6.84
  • P/E Growth -6.84
  • Net Income $-75,521,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Aerovate Therapeutics, Inc. Frequently Asked Questions

  • What is the Aerovate Therapeutics, Inc. stock price today?

    Today's price of Aerovate Therapeutics, Inc. is $2.62 — it has decreased by -1.5% in the past 24 hours. Watch Aerovate Therapeutics, Inc. stock price performance more closely on the chart.

  • Does Aerovate Therapeutics, Inc. release reports?

    Yes, you can track Aerovate Therapeutics, Inc.'s financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Aerovate Therapeutics, Inc. stock forecast?

    Watch the Aerovate Therapeutics, Inc. chart and read a more detailed Aerovate Therapeutics, Inc. stock forecast to see what analysts suggest you do with its shares.

  • What is Aerovate Therapeutics, Inc. stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Aerovate Therapeutics, Inc. stock ticker.

  • How to buy Aerovate Therapeutics, Inc. stocks?

    Like other stocks, AVTE shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Aerovate Therapeutics, Inc.'s EBITDA?

    Aerovate Therapeutics, Inc. measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Aerovate Therapeutics, Inc.’s financial statements.

  • What is the Aerovate Therapeutics, Inc.'s net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Aerovate Therapeutics, Inc. stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Aerovate Therapeutics, Inc.'s financials relevant news, and technical analysis. Aerovate Therapeutics, Inc.'s technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Aerovate Therapeutics, Inc. stock currently indicates a “sell” signal. For more insights, review Aerovate Therapeutics, Inc.’s technical analysis.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.